HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $16.
August 08, 2023 | 4:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inozyme Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $16.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Inozyme Pharma. The maintained price target of $16 indicates the firm's confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100